Everlab, a three-year-old Australian longevity startup offering AI-powered health diagnostics, announced a $65 million Series A funding round led by Airtree Ventures with participation from UK and European investors and high-profile angel investor Pat Cummins.
- Everlab provides AI-enhanced biomarker diagnostics and personalized health plans.
- Series A led by Airtree Ventures with UK and European backers including Plural and b2venture.
- Funds support UK expansion and enhanced clinical and digital infrastructure.
What happened
Everlab secured $65 million in a Series A funding round led by Airtree Ventures, alongside UK fund Plural, European investor b2venture, Left Lane Capital, and several angel investors including Australian cricket captain Pat Cummins. This follows previous fundraising rounds including a $3 million pre-Seed in December 2023 and a $15 million Seed round in July 2025.
The Melbourne-based startup specializes in AI-powered preventive health diagnostics, delivering services such as genetics tests, MRI scans, and packaged health assessments. Everlab’s digital platform integrates diagnostics, clinical care, and continuous AI-driven health management, serving over 20,000 clients across Australia and New Zealand.
Why it matters
Everlab addresses fragmentation in healthcare by centralizing diagnostic data, clinical advice, and personalized health plans into a seamless digital experience. This enables early detection of health issues, with more than 25% of clients discovering previously undetected conditions through its testing programs.
The involvement of prominent investors like Pat Cummins highlights growing confidence in the longevity and health tech sector within Australia. The significant capital injection will enable Everlab to enhance clinical infrastructure and technology, positioning it as a leader in AI-driven health diagnostics and preventive care in new international markets.
What to watch next
Everlab’s upcoming focus will be executing its UK market entry and scaling its AI-health platform across multiple regions. Investors and industry observers will monitor how effectively the company can replicate its Australian and New Zealand success abroad.
Further developments will also include advancements in its digital app capabilities and expansion of its integrated health network, which currently connects with over 1,850 providers and 180 clinicians. Ongoing innovation and partnership growth will be critical factors for Everlab’s potential to become a global generational health business.